KLAS-TELECOM
18.9.2018 07:02:10 CEST | Business Wire | Press release
Klas Telecom announced today they will supply the TRX Connected Transportation Platform to global engineering house Ikusi for a project to upgrade the passenger information systems onboard Renfe train fleets. Under a Memorandum of Understanding, Klas Telecom’s TRX platform will provide an onboard Wi-Fi infrastructure that improves connectivity to and within the train so that passengers have a better user experience accessing the mobile information and services they need. Klas Telecom and Ikusi have enjoyed a longstanding relationship in which they have worked together to design and develop bespoke solutions to deliver the exacting requirements stipulated by Ikusi’s railway customers.
Ikusi selected Klas Telecom’s TRX R6 as the key component of the onboard passenger Wi-Fi system. The TRX R6 will deliver reliable, high-bandwidth and low-latency connectivity to the train. Another key component of the passenger Wi-Fi system is the software-defined wide area network (SDWAN) feature of the TRX operating system, KlasOS. The KlasOS SDWAN aggregates WAN links and manages multiple wireless bearers in order to provide the train both higher throughput and availability of the offboard WAN link. Klas Telecom’s advanced SDWAN technology leverages any available Internet connection, whether in-station Wi-Fi or 3G/4G LTE connections. The KlasOS SDWAN feature seamlessly routes traffic over uncongested links to ensure that passengers stay connected at all times whether checking e-mails, updating social media, remote working over VPN or making a video call.
“Our partnership with Klas Telecom has gone from strength to strength in recent years,” Ikusi Director of Railway Solutions José Morales said. “We can count on their competence to develop the most appropriate solution to meet the project requirements every time. This Memorandum of Understanding ensures that Ikusi continues to work closer than ever to Klas Telecom, ultimately resulting in greater passenger satisfaction for our customers.”
Brendan Fleming, Klas Telecom Director of Business Development for Transportation, added, “Working with a partner like Ikusi allows us to demonstrate what we do best: developing and supplying the latest cutting-edge technology as part of an onboard Wi-Fi solution, allowing the end customer to provide an optimum passenger experience.”
You can view Klas Telecom’s TRX platform this week at InnoTrans 2018 in Hall 7.1B at Messe Berlin.
More About Klas Telecom
With a background in satellite communications, Klas Telecom is an engineering and design company with over 25 years of experience developing innovative communications solutions for the network edge. Klas Telecom delivers connectivity to communications black spots and austere environments where low size, weight, power and ruggedization are required. The company specializes in integrating enterprise networking capabilities from global IT leaders with in-house hardware and software platforms designed and proven against the most stringent environmental requirements. With over 80% of the company dedicated to technology development, Klas Telecom is able to stay on the forefront of the deployable communications technology. Klas Telecom operates in the public safety, transportation and U.S. and international defense markets. The company employs staff across four offices located in Washington, DC; Herndon, VA; Tampa, FL; and Dublin, Ireland. www.klastelecom.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180917005821/en/
Contact:
Klas Telecom Carrie Sarver Hall | VP of Marketing and Communications 202-288-6342 carrie.hall@klastelecom.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents23.4.2026 13:29:00 CEST | Press release
Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agentsA manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol’s clinical development under FDA Fast Track designationThe program demonstrates GE HealthCare’s commitment to advancing novel imaging agents to address unmet patient needs GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by t
Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform23.4.2026 13:13:00 CEST | Press release
New structure to drive AI-powered innovation and international expansion Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics. By automating patient management, scheduling, and administrative workflows, it enables healthcare professionals to focus entirely on patient care. A core element of the new strategy is a strong focus on Artificial Intelligence. Clinicore is evolving into a smart assistant, utilizing AI-driven features for automated treatment documentation, intelligent onboarding tools, and advanced process automation. This ensures that clinics can operate at maximum efficiency
NIQ Launches Commerce Lab to Build the Data and Measurement Layer for AI-Driven Commerce23.4.2026 13:00:00 CEST | Press release
NielsenIQ (NYSE: NIQ) today announced the launch of NIQ Commerce Lab, where the company is building the technology infrastructure for AI-driven commerce. The Lab will develop the data platforms, APIs, and measurement systems that power how products are discovered, evaluated, and purchased in AI-mediated environments. This includes what the industry often refers to as agentic commerce, but extends across quick commerce, social commerce, and other emerging channels—where AI is becoming the common layer shaping how consumers navigate choices and how decisions are made in real time. AI systems are rapidly moving from supporting decisions to making them—playing an increasingly central role in how commerce operates. Their effectiveness depends on the intelligence behind them. AI is Becoming the Operating Layer of Global Commerce NIQ ensures that the intelligence behind these systems is accurate, complete, and grounded in real-world behavior—reflecting how consumers actually buy, what product
Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights23.4.2026 12:10:00 CEST | Press release
Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs. 2024 - Rare sales at €906m, growing 22.3% vs. 2024 Giuseppe Accogli leaving to pursue another opportunity, Group CFO Jean-Marc Bellemin named Interim CEO while new CEO search is underway Record €885m Research & Development (R&D) investment underscores continued commitment to innovation across respiratory, rare disease and specialty care Sustainability leadership further strengthened through B Corp recertification and progress on Carbon Minimal Inhaler (CMI) innovation Chiesi Group (“Chiesi”), an international research‑focused biopharmaceutical company and certified B Corp, today announced its financial results for the year ended 31 December 2025. Chiesi reported €3.625 billion in consolidated revenues,
REPLY S.p.A.: Shareholders’ Meeting Approves the 2025 Financial Statements23.4.2026 12:05:00 CEST | Press release
Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);Group net profits of €250.9 million (€211.1 million in 2024).Approval of the proposal to distribute a dividend of €1.35 per share.Approval of the plan for the purchase and/or disposal of treasury shares. The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] held today approved the Financial Statements for the financial year 2025, confirming the distribution of a gross dividend of €1.35 per share. The dividend will be paid on 20 May 2026, with dividend date set on 18 May 2026 (record date on 19 May 2026). Approval of the 2025 financial statements The Reply Group closed the 2025 financial year with a consolidated turnover of €2,483.6 million, recording a 8.0% increase compared to €2,300.5 million in 2024. Consolidated EBITDA was €467.6 million, up 13.9% compared to €410.6 million recorded for the year 2024. EBIT, from January to December, was €397.1 million, up 18.5% compared to €330.4 million recorded for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom